Pascal Biosciences Inc (TSE:NEVI)
:NEVI
Want to see TSE:NEVI full AI Analyst Report?
NEVI Stock Chart & Stats
C$0.07
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.07
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.10
Previous CloseN/A
Volume0.00
Average Volume (3M)55.49K
Market Cap
C$1.19M
Enterprise ValueC$1.30M
Total Cash (Recent Filing)C$102.17K
Total Debt (Recent Filing)C$244.21K
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Jul 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding39,662,727
10 Day Avg. Volume84,932
30 Day Avg. Volume55,489
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.05
Price to Sales (P/S)1.17
P/FCF Ratio31.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth AcceleratingAccelerating top-line growth indicates the company is gaining traction in its market and beginning to scale revenue. Sustained revenue expansion improves the ability to cover fixed costs, supports operating leverage, and is a durable driver of future margin recovery if paired with consistent execution.
Positive Operating & Free Cash Flow In 2025Conversion to positive operating and free cash flow shows improved cash generation and discipline versus prior years. Durable FCF reduces immediate funding needs, enhances optionality for reinvestment, and provides a clearer runway for the company to pursue profitable scaling if cash generation persists.
Leverage Manageable And ImprovingDeclining leverage improves balance sheet resilience and financial flexibility, lowering interest and refinancing risk over time. A more conservative capital structure supports investment in growth and cushions against operating volatility, provided the company sustains profitability improvements.
Bears Say
Persistent UnprofitabilityDespite progress, the company remains materially unprofitable with negative net margins and historical negative ROE. Structural profitability must improve to cement the balance sheet recovery; continued losses could erode equity and force dilutive financing or cost-cutting that hinders growth.
Sharp Gross Margin DeteriorationA dramatic gross margin decline signals structural cost, pricing, or product-mix problems that directly compress sustainable profitability. If margins remain depressed, the company will struggle to translate revenue growth into durable profits without pricing power, cost control, or a change in mix.
Modest Scale Of Cash Generation Vs VolatilityWhile 2025 cash flow improved, the absolute cash-generation level is small and prior-year volatility highlights execution risk. If cash conversion reverses, the company may need external funding, which could dilute shareholders or constrain strategic initiatives over the medium term.
Pascal Biosciences Inc News
NEVI FAQ
What was Pascal Biosciences Inc’s price range in the past 12 months?
Pascal Biosciences Inc lowest stock price was C$0.03 and its highest was C$0.10 in the past 12 months.
What is Pascal Biosciences Inc’s market cap?
Pascal Biosciences Inc’s market cap is C$1.19M.
When is Pascal Biosciences Inc’s upcoming earnings report date?
Pascal Biosciences Inc’s upcoming earnings report date is Jul 23, 2026 which is in 61 days.
How were Pascal Biosciences Inc’s earnings last quarter?
Currently, no data Available
Is Pascal Biosciences Inc overvalued?
According to Wall Street analysts Pascal Biosciences Inc’s price is currently Overvalued.
Does Pascal Biosciences Inc pay dividends?
Pascal Biosciences Inc does not currently pay dividends.
What is Pascal Biosciences Inc’s EPS estimate?
Pascal Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pascal Biosciences Inc have?
Pascal Biosciences Inc has 39,662,727 shares outstanding.
What happened to Pascal Biosciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pascal Biosciences Inc?
Currently, no hedge funds are holding shares in TSE:NEVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pascal Biosciences Inc
Nevis Brands Inc. develops and markets cannabis products in the United States. Its flagship brand is Major, a cannabis beverage. The company was formerly known as Pascal Biosciences Inc. and changed its name to Nevis Brands Inc. in June 2023. Nevis Brands Inc. is headquartered in Seattle, Washington.
Technical Analysis
TAAT Global Alternatives
―
West Island Brands Inc
―
Modern Meat
―
Lifeist Wellness
―
Element Nutritional Sciences Inc
―
Options Prices
Currently, No data available
---